Announcements
- Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
- Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
- Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
- Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
- Terns Pharmaceuticals Announces Leadership Changes
- Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
- Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
More ▼
Key statistics
As of last trade Terns Pharmaceuticals Inc (430:DUS) traded at 7.70, -15.38% below its 52-week high of 9.10, set on Jul 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.70 |
---|---|
High | 7.70 |
Low | 7.70 |
Bid | 7.75 |
Offer | 8.00 |
Previous close | 7.65 |
Average volume | 50.00 |
---|---|
Shares outstanding | 64.68m |
Free float | 63.52m |
P/E (TTM) | -- |
Market cap | 623.49m USD |
EPS (TTM) | -1.26 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 08:10 BST.
More ▼